INNOSIGN
InnoSIGN is a manufacturer of precision medicine for diagnostics and drug development applications.
INNOSIGN
Industry:
Biotechnology Life Science Medical
Founded:
2020-01-01
Address:
Eindhoven, Noord-Brabant, The Netherlands
Country:
The Netherlands
Website Url:
http://www.innosignbio.com
Status:
Active
Contact:
+31 40 273 01 55
Total Funding:
7.33 M EUR
Investors List
Life Science Angels
Life Science Angels investment in Series A - InnoSIGN
Thuja Capital
Thuja Capital investment in Series A - InnoSIGN
Brabant Development
Brabant Development investment in Series A - InnoSIGN
Casdin Capital
Casdin Capital investment in Series A - InnoSIGN
Official Site Inspections
http://www.innosignbio.com
- Host name: 85.10.159.166.nl.transip.me
- IP address: 85.10.159.166
- Location: France
- Latitude: 48.8582
- Longitude: 2.3387
- Timezone: Europe/Paris
More informations about "InnoSIGN"
InnoSIGN
We are passionate to bring to market our OncoSIGNal pathway activity profiling technology contributing to a better understanding of disease mechanisms in oncology. OncoSIGNal enables next generation precision medicine by …See details»
InnoSIGN - Crunchbase Company Profile & Funding
InnoSIGN is an mRNA-based pathway activity profiling technique that aims to transform precision medicine by providing greater insight into disease causes. The company proposes to use its …See details»
InnoSIGN - LinkedIn
InnoSIGN is a biotech company that takes a biology-first approach to analyzing the relationships and interactions between signaling pathways to discern a series of disease driver events. Our ...See details»
InnoSIGN - Overview, News & Competitors | ZoomInfo.com
Mar 27, 2024 View InnoSIGN (www.innosignbio.com) location in Netherlands , revenue, industry and description. Find related and similar companies as well as employees by title and much …See details»
InnoSIGN Company Profile 2024: Valuation, Funding
Information on valuation, funding, cap tables, investors, and executives for InnoSIGN. Use the PitchBook Platform to explore the full profile.See details»
InnoSIGN - VentureRadar
"The InnoSIGN team is committed to transform cancer care by enabling personalized targeted therapy options through OncoSIGNal pathway activity profiling. OncoSIGNal helps to gain …See details»
InnoSIGN: Drug pipelines, Patents, Clinical trials - Synapse
Aug 22, 2023 The purpose of this prospective, parallel-group, cohort study is to implement phenotype-guided targeted therapy based on functional signal transduction pathway (STP) …See details»
InnoSIGN - High Tech Campus
InnoSIGN commercializes its proprietary mRNA-based OncoSIGNal pathway activity profiling technology, revolutionizing precision medicine by obtaining more insight into the mechanisms of disease.See details»
InnoSIGN - LinkedIn India
InnoSIGN | 579 followers on LinkedIn. Revolutionizing Precision Medicine | InnoSIGN is a start-up company based at the High Tech Campus in Eindhoven (NL) and in Mason, Ohio (US). We …See details»
InnoSIGN - Scientist.com
If your organization has a Scientist.com marketplace, you can log in here to order products and services directly. If you're interested in ordering custom research services from suppliers in the …See details»
Contact us - InnoSIGN
Get in touch [email protected] InnoSIGN Inc. 251 Little Falls Drive Wilmington, DE, 19808 United States InnoSIGN B.V. High Tech Campus 11 5656 AE Eindhoven The NetherlandsSee details»
InnoSIGN Completes Spin-Out from Philips with an $8M Series A …
Mar 22, 2022 InnoSIGN utilizes its proprietary database with over 100,000 pathway activity profiles for drug development and diagnostics to predict patient response to targeted therapies …See details»
InnoSIGN | CipherBio
Explore InnoSIGN's investment information, scientific platforms, therapeutic approaches, indications and more here!See details»
InnoSIGN Completes Spin-Out from Philips with an $8M Series
Mar 22, 2022 InnoSIGN utilizes its proprietary database with over 100,000 pathway activity profiles for drug development and diagnostics to predict patient response to targeted therapies …See details»
InnoSIGN completes spin-out from Philips, $8M Series A
GlobeNewsWire: March 22, 2022 InnoSIGN Completes Spin-Out from Philips with an $8M Series A Financing to Revolutionize Precision Medicine through its OncoSIGNal Pathway Activity …See details»
InnoSIGN | VentureRadar
The InnoSIGN team is committed to transform cancer care by enabling personalized targeted therapy options through OncoSIGNal pathway activity profiling. OncoSIGNal helps to gain …See details»
Platform - InnoSIGN
InnoSIGN’s Comprehensive Pathway Analysis (CPA) platform unlocks the true value next generation sequencing (NGS) to revolutionize how patients are diagnosed, stratified, and treated.See details»
Science - InnoSIGN
Aberrant single pathways or cooperation or crosstalk between multiple pathways (MAPK + TGFβ) are know to cause disease. Aberrant pathway signaling is linked to diseases across almost all …See details»
News Archive - InnoSIGN
InnoSIGN receives grant of almost €700K for ovarian cancer multicenter trialSee details»